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Abstract
Introduction: Cystatin C could be a relevant residual glomerular filtration rate marker during hemodialysis (HD), and a 
high cytokine plasma (p) rate is associated with an increase in mortality during sepsis. To the best of our knowledge, 
cytokines and cystatin C kinetics during and after HD during sepsis have never been studied. In this study, we 
described p cytokines and cystatin C variations during and after hemodialysis in septic-shock patients with acute 
kidney injury (AKI).
Methods: Ten patients, from two tertiary ICUs, with septic shock-related AKI, according to RIFLE class F, were studied. In 
this prospective observational study, blood samples were collected at the start, after 1 hour, 2 hours, and at the end of 
HD with a polymethymethacrylate (PMMA) hemodialyzer (D0, D1, D2, and endD), and 30, 60, 90, 120, and 180 min after 
HD (postD0.5, postD1, postD1.5, postD2, and postD3). We measured p interleukins (IL)-6, IL-8, IL-10, cystatin C, and 
albumin. Results are expressed as variations from D0 (mean ± SD).
Results: During HD, p[IL-6] did not vary significantly, whereas p[IL-8] and p[IL-10] reductions by D1 were 31.8 ± 21.2% 
and 36.3 ± 26%, respectively (P < 0.05 as compared with D0). At postD3, p[IL-8] and p[IL-10] returned to their initial 
values. p[Cystatin C] was significantly reduced from D1 to postD1, with a maximal reduction of 30 ± 6.7% on D2 (P < 
0.05). Norepinephrine infusion rate decreased from D0 to postD3 (0.65 ± 0.39 to 0.49 ± 0.37 μg/kg/min; P < 0.05).
Conclusions: HD allows a transient and selective decrease in p cytokines, which are known as being correlated with 
mortality during septic shock. Because of a significant decrease in p cystatin C during HD, this should not be 
considered as an accurate marker for residual glomerular filtration rate during septic acute renal failure when receiving 
HD with a PMMA hemodialyzer.
Introduction
Sepsis is the leading cause of acute kidney injury (AKI)
[1]. The combination of sepsis and acute renal failure is
associated with high mortality and morbidity [1]. AKI
treatment mostly requires renal-replacement therapy
(RRT). Two modalities of RRT are available in intensive-
care units: continuous RRT (CRRT) using venovenous
hemodiafiltration/hemofiltration or intermittent RRT
(IRRT) using hemodialysis.
Sepsis causes systemic inflammatory response syn-
drome (SIRS), mediated by many biologically active
inflammatory mediators (including cytokines like inter-
l e u k i n s )  [ 2 , 3 ] .  H i g h  p l a s m a  i n t e r l e u k i n  ( I L )  l e v e l s  a r e
associated with increased mortality in human septic AKI
(that is, IL-6, IL-8, and IL-10) [4-8] and might contribute
to the pathogenesis of sepsis-related organ failure, includ-
ing AKI [2,9]. Unfortunately, therapies targeting particu-
lar components of the SIRS-associated cytokine network
have failed, probably because of the dynamic complexity
of SIRS [10-12]. New data suggested that RRT could
modulate SIRS via nonspecific extracorporeal removal of
cytokines: this has renewed interest in this mediator-
directed therapy [13,14].
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In contrary to CRRT, sparse information is available
concerning IRRT and cytokine levels during sepsis. Haase
et al. [15], in a preliminary study, suggested that the use of
hemodialyzers with high-molecular-weight cutoff mem-
branes may lead to significant removal of plasma cytok-
ines during hemodialysis. However, to the best of our
knowledge, data concerning the kinetics of plasma cytok-
ines after hemodialysis in sepsis patients with AKI are
dramatically lacking. In patients with chronic renal fail-
ure, IRRT is followed by a fast but mild increase in serum
urea or potassium levels during the first hour ("rebound"
phenomenon) [16,17]. Similarly, given the high level of
cytokine production in septic tissues, plasma cytokine
levels may dramatically vary after IRRT.
Estimation of residual glomerular filtration rate (rGFR)
in patients with AKI is also a major concern in the ICU.
Cystatin C is a better marker of GFR than is serum creati-
nine in chronic kidney disease, but its involvement in
ARF is still controversial [18,19]. Cystatin C is a middle-
mass molecule (≈13 kDa) that is not supposed to be
removed by the standard hemodialyzer. This characteris-
tic may be of interest when evaluating rGFR, and several
s t u d i e s  s u g g e s t e d  t h a t  cy s t a t i n  C  c o u l d  b e  u s e d  a s  a n
rGFR marker during peritoneal dialysis and intermittent
hemodialysis [20,21]. As cytokines, plasma variations of
cystatin C during IRRT for septic shock-related acute
renal failure have not been studied. In this prospective
observational study, we assessed the per- and postdialysis
kinetic plasma levels of IL-6, IL-8, IL-10, cystatin C, and
albumin in ten patients with septic shock-related AKI
that required RRT.
Materials and methods
Setting and eligibility
This study was a prospective observational case series,
conducted from September 2007 to December 2008 in
the nephrologic and transplantation intensive care unit
(ICU) and the polyvalent ICU units at Toulouse Univer-
sity Hospital (France). To be included in the study,
patients had to reach the following criteria: (1) severe
sepsis or septic shock of <24 h, as defined by the criteria
of the American College of Chest Physicians/Society of
Critical Care Medicine Consensus Conference [22]; (2) a
need for renal-replacement therapy defined as Failure
according to the RIFLE criteria [23] (oliguria < 0.3 ml/kg/
h during 24 hours, or anuria during 12 hours, or threefold
increase in creatinemia); and (3) an age of older than 18
years. Exclusion criteria were as follows: pregnancy, pre-
vious chronic renal failure requiring hemodialysis, liver
cirrhosis, acute pancreatitis, organ transplantation, and/
or immunosuppressive therapy. As requested by our local
institutional research committee (Centre Hospitalier
Universitaire de Toulouse, Toulouse, France), after
approval, informed consent was obtained from each
patient's next of kin. This study was performed in accor-
dance with the Helsinki declaration.
The following data for all patients were recorded: age,
gender, diagnosis, SAPS 2, and SOFA scores at inclusion.
Biomarkers and treatments received were collected from
the start of HD, at the end of HD, and for 3 hours after the
end of HD. Arterial line and central venous catheters
allowed documentation of mean arterial pressure (MAP)
and drug infusions, respectively. Cardiac-output mea-
surements were obtained, if necessary, via transthoracic
echography or a Pulse-Indexed Continuous Cardiac Out-
put (PiCCo) monitor (Pulsion; Medical Systems AG,
Munich, Germany). Throughout the ICU hospitalization,
the patients were resuscitated, if needed, to reach hemo-
dynamic goals as recommended by the international
guidelines for septic shock and were under the responsi-
bility of an ICU-qualified senior physician [24]. Blood
cultures and specific bacterial samples were collected at
various times to specify the etiology of the infection. If
known, the site of infection was recorded. None of the
patients received enteral or parenteral nutrition before,
within, and for the 3 hours after dialysis. Supplements of
trace elements, water, and fat-soluble vitamins were
given. Continuous intravenous insulin therapy was deliv-
ered if necessary to achieve a normal glycemia (range, 1
to 1.5 g/L).
Protocol and intermittent renal-replacement therapy
D0 was considered to be the start of hemodialysis. Mean
arterial pressure (MAP), heart rate (HR), dobutamine
and/or norepinephrine dose, and fluid infusion were
recorded at D0, at every hour during hemodialysis (D1;
D2), at the end of HD (endD), and at 30, 60, 90, 120, and
180 minutes after completing HD (postD0.5, postD1,
postD1.5, postD2, and postD3, respectively). During
hemodialysis, conductivity, Kt, and dialysance were
recorded.
According to the literature, hemodynamic stability dur-
ing hemodialysis has been optimized by using several
methods: arterial- and venous-circuit simultaneous con-
nection, high conductivity, an ultrafiltration-free first
hour, circuit-to-body temperature difference of 2°C, and
high dialysate calcium concentration (1.75 mM) [25].
Blood flow was started at 250 ml/min and was
enhanced according to hemodynamic tolerance. Ultrafil-
tration was based on the individual patient's fluid status.
Duration of HD was 3 hours.
Vascular access for renal replacement was obtained by
using a double-lumen venous cannula (Hemoaccess 13 F,
25 cm, Hospal). An Integra generator was used for the
hemodialysis (Hospal; Gambro Renal Products, Antwerp,
Belgium). We used a polymethylmetacrylate (PMMA)
membrane: Filtrizer BK-1, 6F; Toray Industries, Tokyo,
Japan. The ability of the PMMA membrane to removeMayeur et al. Critical Care 2010, 14:R115
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cytokines during both IRRT for chronic renal failure and
CRRT during septic AKI has been described [26,27]. The
PMMA dialyzer has been reported to adsorb proinflam-
matory cytokines or free light chains during multiple
myeloma and is specific insofar as it can remove proteins
by adsorption as well as permeation [28-30]. The extra-
corporeal circuit was anticoagulated with a continuous
unfractionated heparin infusion, with the anticoagulation
regimen adjusted to the individual patient's needs.
Biologic and cytokine analyses
Blood samples were collected in nonheparinized tubes
and were immediately centrifuged in the ICU at 4,000
rpm for 10 minutes (4°C). Plasma was subsequently
stored at -70°C until assayed. Cystatin C measurements
were obtained by using PETIA (particle-enhanced tur-
bidimetric immunoassay) with a cystatin C reagent (Cys
C Immunoparticles; Dako Inc., Glostrup, Denmark) on a
ABXPentra 400 chemistry analyzer (Horiba Medical,
Kyoto, Japan). Serum albumin concentrations were quan-
tified by nephelometry (Immage 800; Beckman Coulter,
Villepinte, France). Plasma (p) cytokine levels were mea-
sured with enzyme-linked immunosorbent assays (ELI-
SAs), according to the manufacturer's instructions (BD-
Biosciences, Le Pont De Claix, France).
Measurements and statistics
Continuous variables during and after dialysis were com-
pared by using Friedman nonparametric tests. If signifi-
cant, the Dunn post hoc test was applied. Univariate
analysis of D0 data from survivors and nonsurvivors was
performed by using the nonparametric Mann-Whitney
test. Cytokines, albuminemia, and cystatin C were
expressed as relative concentration from baseline value
(D0). Results are expressed as mean ± standard deviation.
A P value < 0.05 was considered statistically significant.
The data were analyzed by using GraphPad Prism (ver-
sion 4 2005; Graphpad Software Inc., San Diego, CA,
USA).
Results
Patients and hemodialysis
T en patients with septic shock in whom AKI developed
were enrolled in this study. Their main demographic and
clinical data at baseline are summarized in Tables 1 and 2.
In brief, intermittent hemodialysis was not deleterious
to their hemodynamics, as suggested by the stability of
MAP (see Figure 1a). A significant decrease was observed
in the norepinephrine infusion rate during the 6 hours of
the study (0.65 ± 0.39 vs. 0.49 ± 0.37 μg/kg/min; P < 0.01;
Figure 1b). Fluid loading between D0 and endD, and
between endD and postD3 was 75 ± 169 and 125 ± 143
ml, respectively. This low fluid intake during IRRT is
explained by the mixed venous oxygen saturation (SvO2)
being high at D0 (77.2 ± 10.3 mm Hg) after previous ade-
quate resuscitation. Atrial fibrillation (AF) was apparent
i n  f o u r  p a t i e n t s  a t  D 0 .  A F  r e s o l v e d  i n  o n e  p a t i e n t  a t
postD1, but persisted in the other three despite hemody-
namic improvement.
Only one patient required 1,900 ml of ultrafiltration.
Conductivity at D0 was 146 ± 0.43 mEq/L. Mean
dialysance and Kt were 152 ± 17 and 28 ± 4.8, respectively.
The urea-reduction fraction was 48.5% (P < 0.003; Figure
1c).
Last, in-hospital mortality was 60%. Also, at D0, no dif-
ference was noted between survivors and nonsurvivors
according to plasma IL-6, IL-8, and IL-10 levels and other
biologic characteristics (data not shown).
Cytokines, albumin, and cystatin C kinetics
At D0, the plasma concentrations of IL-6, IL-8, and IL-10
were 840 ± 540, 666 ± 586, and 178 ± 173 pg/ml. Interleu-
kins, cystatin C, and albuminemia plasma concentrations
are expressed as variations from the baseline value (D0)
(Figures 2 and 3).
Table 1: Characteristics of patients
Characteristics Data
Age (years) 67.40 ± 7.21
Sex ratio (F/M) 3/7
SAPS 2 at D0 79.11 ± 4.73
SOFA at D0 14.6 ± 0.8
Mechanical ventilation 9/10
Norepinephrine 10/10
Dobutamine 1/10
In-hospital mortality (%) 60
Infectious disease: localization
Pulmonary 5/10
Peritoneal 3/10
Cutaneous 2/10
Urologic 1/10
Bilirubinemia at D0 (mg/L) 19.9 ± 19.1
Factor V at D0 (%) 64.2 ± 24.1
CRP at D0 (mg/L) 240.8 ± 103.9
Leukocytes at D0 (cells/μl) 23,981 ± 13,726
Hemoglobinemia at D0 (g/L) 10.9 ± 0.38
p[IL-6] at D0 (pg/ml) 840 ± 539
p[IL-8] at D0 (pg/ml) 724 ± 572
p[IL-l0] at D0 (pg/ml) 178 ± 173
F, female; IL, interleukin; M, male; SAPS 2, Simplified Acute 
Physiology Score; SOFA, Sequential Organ Failure score.
Values expressed as mean ± standard deviation.Mayeur et al. Critical Care 2010, 14:R115
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During HD, p[IL-6] did not vary significantly, whereas
p[IL-8] decreased with hemodialysis, followed by a pro-
gressive increase from endD to postD3. At D1, endD, and
postD3, p[IL-8] was 68.2 ± 21.2 (vs. D0, P < 0.05), 71.1 ±
21.7, and 96.3 ± 35.3%, respectively.
After a maximal decrease at D1, p[IL-10] increased
between D2 and postD1.5. The p[IL-10] at D1, endD, and
postD3 was 63.7 ± 26, 83.3 ± 68.7 (vs. D0, P < 0.05), and
83.3 ± 55.6%, respectively (see Figure 2).
p[Cystatin C] was significantly reduced from D1 to
postD1 with a maximal reduction of 30 ± 6.7% at D2 (vs.
D0, P < 0.05), whereas no modification of albuminemia
occurred within the study period (P = ns; see Figure 3a,
b).
Discussion
Inside and outside the hospital, severe sepsis and septic
shock remain challenging for practitioners, given their
high mortality, often related to multiple organ failure,
including renal loss of function [1]. High plasma IL-6, IL-
8, and IL-10 levels have recently been associated with
increased mortality in human sepsis-related ARF [31].
According to the concept of "peak concentration," inten-
sivists try to decrease all circulating mediators at high
plasma concentrations, including pro- and antiinflamma-
tory molecules [32]. Hemofiltration (CRRT) is supposed
to be the best way to remove cytokines compared with
hemodialysis (IRRT), which is based mainly on diffusion.
Thus, the efficiency of plasma cytokines removal has
mostly been assessed during CRRT. To our knowledge,
only one trial has described the kinetics of plasma cytok-
ines during IRRT for septic shock-related AKI [15], and
data concerning plasma cytokine levels after hemodialy-
sis are lacking.
In our study , we observed that for IRRT , membranes
that leak proteins only partially and transiently decreased
plasma IL-8 and IL-10, although not IL-6 levels. In our
ten patients, plasma IL-8 and IL-10 decreased rapidly
(before D2) and significantly after the beginning of IRRT
(see Figure 2). Interestingly, plasma IL-10 levels started to
increase before the end of hemodialysis. We did not ana-
lyze the effluent and the membrane, but we suggest that
dramatic coating of the membrane with IL-10 (and other
middle-mass proteins) had occurred. This coating could
have led to the early decrease in the adsorptive properties
of the PMMA membrane. As IL-10 is larger than IL-8 (19
vs. 8 kDa, respectively), its removal from the PMMA
membrane is probably based mainly on adsorption. In a
recent study, Nakada et al. have shown prolonged
cytokine elimination during CRRT when using a PMMA-
based hemodialyzer, but the extent of adsorption and
convection clearance were not clarified [26]. In another
way, other molecules, which might have participated in
the generation of IL-8 and IL-10, could have been
removed. Their removal, rather than having a direct
effect on cytokines, might have been responsible for our
findings. Finally, a high level of IL-6 or IL-10 generation
that was sufficient to exceed removal might have been
partially responsible for the lack of cytokine elimination.
However, two findings argue against this hypothesis:
plasma IL-6 did not increase after IRRT, and the ratio
between plasma cytokines (especially IL-8) and cystatin
C levels suggests a weight-dependent removal. Cystatin C
production is constant, and its variations are almost inde-
Table 2: Characteristics of patients at D0, endD, and post-D3
Characteristics D0 EndD Post-D3
Cystatin C (mg/L) 3.73 ± 1.17 2.65 ± 0.74a 3.25 ± 0.94
Urea (mM) 28.8 ± 10.7 14.8 ± 6.3a 17.4 ± 7.3
Creatinemia (μM) 399 ± 148 230 ± 74 257 ± 83
Bicarbonatemia (mM) 15.7 ± 4 22.9 ± 1.8a 21.7 ± 4a
Albuminemia (g/L) 18.8 ± 4.5 19.9 ± 5.3a 17.7 ± 5.1
Norepinephrine rate (μg/kg/min) 0.65 ± 0.12 0.57 ± 0.38 0.49 ± 0.37
MAP (mm Hg) 80.1 ± 13.7 80.7 ± 10.8 81 ± 16.4
Heart rate (beats/min) 110 ± 20 113 ± 19 103 ± 17
Urinary output (ml/h) 17 ± 14.9 15 ± 12 24.5 ± 17.8
Lactatemia (mM) 3.2 ± 1.8 2.4 ± 1.5
pH 7.27 ± 0.08 7.39 ± 0.05b
SvO2 (%) 77.2 ± 10.3 77.9 ± 12
MAP, mean arterial pressure; SvO2, mixed venous oxygen saturation. Results are expressed as the mean ± standard deviation. aP < 0.05 versus 
D0 (Friedman test). bP < 0.05 versus D0 (Wilcoxon signed-rank test).Mayeur et al. Critical Care 2010, 14:R115
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pendent of sepsis [18]. Altogether, these data suggest that
clearance of IL-6 and IL-10 was absent and transient,
respectively.
As mentioned earlier, the kinetics of plasmatic cytokine
levels after IRRT in patients with septic shock-related
ARF have not been previously reported. Given the large
amount of cytokines produced during sepsis, we hypoth-
esize that cytokines may also be affected by the rebound
phenomenon of small molecules (that is, urea and potas-
sium), which occurs within the first hour after intermit-
tent dialysis for chronic renal failure [16]. In brief, the
rebound phenomenon is related to the shift of soluble
molecules from tissues to the intravascular compartment
through a concentration gradient until a new equilibrium
occurred. Cytokines are heavier and less diffusive mole-
cules than urea or potassium; thus, this rebound could
reflect a cytokine concentrations gradient between tissue
and vascular compartments that appeared during hemo-
dialysis. After HD, a progressive release of cytokines from
dialysis-induced hypoperfused tissue to the intravascular
compartment may occur until a new equilibrium is
reached. In these ten patients, we observed an upward
trend (but not significant) of p[IL-8] and p[IL-10] (+15.2
and +10.45%, respectively) within the first 90 minutes
after hemodialysis. Of note, the interindividual plasmatic
cytokines variability may have hampered these data from
reaching significance, and thus from revealing a statisti-
cally significant cytokine rebound. Nevertheless, we
Figure 1 Hemodynamic, urea, and kalemia variations during and after hemodialysis. Mean arterial pressure (a) and norepinephrine infusion 
rate (b) at the start (D0), the end (endD), and 3 hours (postD3) after hemodialysis. Values are expressed as mean ± SEM. Urea (c) and kalemia (d) at the 
start, the end, 1 hour, and 3 hours after hemodialysis, D0, end D (clear), postD1 and postD2 (dark), respectively. Values are expressed in boxplots. *P < 
0.05; Friedman test.Mayeur et al. Critical Care 2010, 14:R115
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observed that all the cytokines we tested for returned to
baseline values after postD3, highlighting for the first
time the transient effect of hemodialysis on plasma
cytokine concentration.
In our study, we showed that plasma cystatin C was sig-
nificantly decreased during hemodialysis when using a
PMMA membrane, with a maximal reduction of 30%,
almost equal to IL-10. This decrease in cystatin C is
mostly explained by its molecular mass of about 13 kDa
and the in vivo filtration cutoff of the BK-1,6 F mem-
brane, estimated at 20 kDa (data provided by the manu-
facturer). This finding, which should be confirmed by
further studies, highlights the inability of cystatin C to
assess rGFR in patients with ARF treated with a PMMA
hemodialyzer.
Mortality was high (60%) but correlated with disease
severity. We used previously described IRRT modalities
adapted to hypotensive patients [25]. Herein, although
our study was not designed to analyze clinic features, we
did not identify any worsening of hemodynamic parame-
ters (MAP, HR, NE infusion, SvO2) during HD (see Figure
1a, b). Moreover, amounts of NE infused at postD3 were
significantly decreased versus D0 (P < 0.01, Figure 1b),
without any significant fluid-loading challenge. Cytokine
removal is thought to be the major component of the
beneficial effect of RRT in sepsis, but, in our study,
improvement of hemodynamic status was not correlated
with cytokine reduction [33-35]. This last observation is
in agreement with a study conducted by Klouch et al.
[36], in which hemodynamic improvement during CRRT
was not correlated with TNF-α and IL-6 removal.
Conclusions
Our results, which should be confirmed in larger cohort,
strongly suggest that intermittent hemodialysis with
PMMA-based membranes decreases plasma IL-8 and IL-
10 concentrations (in contrast to IL-6). Moreover, we
showed for the first time that only 3 hours after IRRT,
Figure 2 Cytokine variations during hemodialysis. Plasma level of IL-6 (a), lL-8 (b), and IL-10 (c). Results are expressed in percentage of value at D0 
during (clear) and after (dark) hemodialysis as mean ± SEM. *P < 0.05 versus D0. Friedman test.Mayeur et al. Critical Care 2010, 14:R115
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cytokine concentrations revert to baseline levels after an
initial rebound. These results highlight that IRRT is not
associated with prolonged plasma cytokine reductions
during septic shock. Finally, as the plasma cystatin C level
is reduced during IRRT, it is probably not a valid residual
GFR marker during septic ARF requiring IRRT.
Key messages
• Cystatin C is not an accurate residual glomerular fil-
tration rate marker, as the cystatin C plasma value is 
reduced during hemodialysis with a PMMA-based 
membrane.
• Hemodialysis with a PMMA-based membrane 
decreases IL-8 and IL-10 (but not IL-6) plasma levels 
in septic shock patients.
• The decrease in IL-8 and IL-10 plasma levels is tran-
sient, as 3 hours after hemodialysis, plasma IL-8 and 
IL-10 levels have reverted to baseline values.
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